Physician profile
Robert Romanelli
NPI 1144208554
$80,722.84
in general payments reported to CMS, 2019-2025
37 companies · $1,347 in 2025
The $1,347 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $28K · 2021: $34K · 2022: $1,115 · 2023: $1,149 · 2024: $1,776 · 2025: $1,347.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,234 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $38.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,233.75 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $38.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $62,182.48 | 2019-2022 | |
| Ge Healthcare | $7,937.00 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $2,929.90 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $872.24 | 2019-2025 | Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $841.63 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Abbvie INC. | $835.13 | 2020-2025 | Ubrelvy, Vraylar, Synthroid |
| Novo Nordisk INC | $565.69 | 2019-2025 | Ozempic, Rybelsus |
| Amgen INC. | $480.98 | 2019-2025 | Repatha, Otezla, Repatha |
| Novartis Pharmaceuticals Corporation | $464.54 | 2019-2025 | |
| Amarin Pharma, INC. | $387.94 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $379.72 | 2019-2025 | Spravato |
| Merck Sharp & Dohme LLC | $315.63 | 2019-2021 | |
| Glaxosmithkline, LLC. | $310.09 | 2020-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Esperion Therapeutics, INC. | $274.51 | 2020-2022 | |
| Pfizer INC. | $253.25 | 2023-2025 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Romanelli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.